Coverage of exploratory CSF proteomics from a Phase 2 study testing daily sensory stimulation for amyloid-positive mild cognitive impairment and suggested effects on lipid transport and myelination biomarkers.
Key Takeaways
- Cognito Therapeutics presented exploratory cerebrospinal fluid proteomics data at AAIC 2026
- Analysis also identified significant enrichment of the Oligodendrocyte/Myelination (M36)
- Increased CSF levels of multiple HDL-like lipid transport proteins